Pathogenesis of inflammatory bowel disease and recent advances in biologic therapies

Duk Hwan Kim, JaeHee Cheon

Research output: Contribution to journalReview article

52 Citations (Scopus)

Abstract

Inflammatory bowel disease (IBD) is a chronic intestinal inflammatory disorder with an unknown etiology. IBD is composed of two different disease entities: Crohn’s disease (CD) and ulcerative colitis (UC). IBD has been thought to be idiopathic but has two main attributable causes that include genetic and environmental factors. The gastrointestinal tract in which this disease occurs is central to the immune system, and the innate and the adaptive immune systems are balanced in complex interactions with intestinal microbes under homeostatic conditions. However, in IBD, this homeostasis is disrupted and uncontrolled intestinal inflammation is perpetuated. Recently, the pathogenesis of IBD has become better understood owing to advances in genetic and immunologic technology. Moreover, new therapeutic strategies are now being implemented that accurately target the pathogenesis of IBD. Beyond conventional immunesuppressive therapy, the development of biological agents that target specific disease mechanisms has resulted in more frequent and deeper remission in IBD patients, with mucosal healing as a treatment goal of therapy. Future novel biologics should overcome the limitations of current therapies and ensure that individual patients can be treated with optimal drugs that are safe and precisely target IBD.

Original languageEnglish
Pages (from-to)25-40
Number of pages16
JournalImmune Network
Volume17
Issue number1
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Biological Therapy
Inflammatory Bowel Diseases
Immune System
Therapeutics
Biological Factors
Biological Products
Ulcerative Colitis
Crohn Disease
Gastrointestinal Tract
Homeostasis
Inflammation
Technology

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

@article{ec9d985dd07745ccbfef125627c076f0,
title = "Pathogenesis of inflammatory bowel disease and recent advances in biologic therapies",
abstract = "Inflammatory bowel disease (IBD) is a chronic intestinal inflammatory disorder with an unknown etiology. IBD is composed of two different disease entities: Crohn’s disease (CD) and ulcerative colitis (UC). IBD has been thought to be idiopathic but has two main attributable causes that include genetic and environmental factors. The gastrointestinal tract in which this disease occurs is central to the immune system, and the innate and the adaptive immune systems are balanced in complex interactions with intestinal microbes under homeostatic conditions. However, in IBD, this homeostasis is disrupted and uncontrolled intestinal inflammation is perpetuated. Recently, the pathogenesis of IBD has become better understood owing to advances in genetic and immunologic technology. Moreover, new therapeutic strategies are now being implemented that accurately target the pathogenesis of IBD. Beyond conventional immunesuppressive therapy, the development of biological agents that target specific disease mechanisms has resulted in more frequent and deeper remission in IBD patients, with mucosal healing as a treatment goal of therapy. Future novel biologics should overcome the limitations of current therapies and ensure that individual patients can be treated with optimal drugs that are safe and precisely target IBD.",
author = "Kim, {Duk Hwan} and JaeHee Cheon",
year = "2017",
month = "1",
day = "1",
doi = "10.4110/in.2017.17.1.25",
language = "English",
volume = "17",
pages = "25--40",
journal = "Immune Network",
issn = "1598-2629",
publisher = "Korean Association of Immunologists",
number = "1",

}

Pathogenesis of inflammatory bowel disease and recent advances in biologic therapies. / Kim, Duk Hwan; Cheon, JaeHee.

In: Immune Network, Vol. 17, No. 1, 01.01.2017, p. 25-40.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Pathogenesis of inflammatory bowel disease and recent advances in biologic therapies

AU - Kim, Duk Hwan

AU - Cheon, JaeHee

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Inflammatory bowel disease (IBD) is a chronic intestinal inflammatory disorder with an unknown etiology. IBD is composed of two different disease entities: Crohn’s disease (CD) and ulcerative colitis (UC). IBD has been thought to be idiopathic but has two main attributable causes that include genetic and environmental factors. The gastrointestinal tract in which this disease occurs is central to the immune system, and the innate and the adaptive immune systems are balanced in complex interactions with intestinal microbes under homeostatic conditions. However, in IBD, this homeostasis is disrupted and uncontrolled intestinal inflammation is perpetuated. Recently, the pathogenesis of IBD has become better understood owing to advances in genetic and immunologic technology. Moreover, new therapeutic strategies are now being implemented that accurately target the pathogenesis of IBD. Beyond conventional immunesuppressive therapy, the development of biological agents that target specific disease mechanisms has resulted in more frequent and deeper remission in IBD patients, with mucosal healing as a treatment goal of therapy. Future novel biologics should overcome the limitations of current therapies and ensure that individual patients can be treated with optimal drugs that are safe and precisely target IBD.

AB - Inflammatory bowel disease (IBD) is a chronic intestinal inflammatory disorder with an unknown etiology. IBD is composed of two different disease entities: Crohn’s disease (CD) and ulcerative colitis (UC). IBD has been thought to be idiopathic but has two main attributable causes that include genetic and environmental factors. The gastrointestinal tract in which this disease occurs is central to the immune system, and the innate and the adaptive immune systems are balanced in complex interactions with intestinal microbes under homeostatic conditions. However, in IBD, this homeostasis is disrupted and uncontrolled intestinal inflammation is perpetuated. Recently, the pathogenesis of IBD has become better understood owing to advances in genetic and immunologic technology. Moreover, new therapeutic strategies are now being implemented that accurately target the pathogenesis of IBD. Beyond conventional immunesuppressive therapy, the development of biological agents that target specific disease mechanisms has resulted in more frequent and deeper remission in IBD patients, with mucosal healing as a treatment goal of therapy. Future novel biologics should overcome the limitations of current therapies and ensure that individual patients can be treated with optimal drugs that are safe and precisely target IBD.

UR - http://www.scopus.com/inward/record.url?scp=85018177979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018177979&partnerID=8YFLogxK

U2 - 10.4110/in.2017.17.1.25

DO - 10.4110/in.2017.17.1.25

M3 - Review article

VL - 17

SP - 25

EP - 40

JO - Immune Network

JF - Immune Network

SN - 1598-2629

IS - 1

ER -